A process for preparation of 2-[N-[(S)-l-ethoxycarbonyl-3-phenylpropyl] - (S) -alanyl]-(1S, 3S, 5S)-2- azabicyclo [3.3.0 ] octane-3-carboxylic acid, ie. Ramipril, involves condensation of an activated derivative of 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-(S)-alanine with racemic (1R*, 3R*, 5R*) -2-azabicyclo [3.3.0] octane-3-carboxylic acid, and then the desired diastereoisomer (la) is separated from the obtained diastereoisomeric mixture of 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl](S) -alanyl] - (1S, 3S, 5S) -2-azabicyclo [3.3.0] octane-3-carboxylic acid (1a) and 2- [N-[(S)-1-ethoxycarbonyl-3-phenylpropyl ] - (S) -alanyl ] - (1R, 3R, 5R) -2- azabicyclo[3.3.0]octane-3-carboxyl ic acid (lb) by treating it with a solvent that selectively dissolves the undesired diastereoisomer (1b) while the diastereoisomer (1a) remains undissolved.
一种制备2-[N-[(S)-1-乙氧羰基-3-苯丙基]-(S)-丙
氨酸]-(1S,3S,5S)-
2-氮杂双环[3.3.0]辛烷-3-羧酸,即
雷米普利的方法涉及将2-[N-[(S)-1-乙氧羰基-3-苯丙基]-(S)-丙
氨酸的活化衍
生物与混合(1R*、3R*、5R*)-
2-氮杂双环[3.3.0]辛烷-3-羧酸进行缩合反应,然后通过用溶剂处理,从得到的2-[N-[(S)-1-乙氧羰基-3-苯丙基]-(S)-丙
氨酸]-(1S,3S,5S)-
2-氮杂双环[3.3.0]辛烷-3-羧酸的二对映异构体混合物中分离所需的对映异构体(1a),即将其与选择性溶解非期望的对映异构体(1b)的溶剂处理,而对映异构体(1a)保持未溶解。